<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
         xmlns="http://purl.org/rss/1.0/"
         xmlns:admin="http://webns.net/mvcb/"
         xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
         xmlns:dc="http://purl.org/dc/elements/1.1/"
         xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">
  <channel rdf:about="https://hstalks.com/rss/by-category/764/">
    <title>Cancer</title>
    <link>https://hstalks.com/category/764/cancer/?biosci</link>
    <description>New and updated series &amp; talks on Cancer from HSTalks&#x27; Biomedical &amp; Life Sciences Collection.</description>
    <admin:generatorAgent rdf:resource="http://www.hstalks.com/" />
    <admin:errorReportsTo rdf:resource="mailto:info@hstalks.com" />
    <sy:updatePeriod>daily</sy:updatePeriod>
    <sy:updateFrequency>1</sy:updateFrequency>
    <sy:updateBase>2006-01-01T12:00+00:00</sy:updateBase>
    <dc:publisher>Henry Stewart Talks</dc:publisher>
    <dc:language>en</dc:language>
    <dc:rights>© Copyright Henry Stewart Talks Ltd.</dc:rights>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
    <prism:copyright>© Copyright Henry Stewart Talks Ltd.</prism:copyright>
    <items>
      <rdf:Seq>
      <rdf:li resource="https://hstalks.com/t/24280/peroxisome-proliferator-activated-receptors-ppar-n/?biosci" />
      <rdf:li resource="https://hstalks.com/t/24313/nuclear-receptor-targeting-drugs/?biosci" />
      <rdf:li resource="https://hstalks.com/t/26095/immunological-biomarkers-in-cabozantinib-and-nivol/?biosci" />
      <rdf:li resource="https://hstalks.com/t/24314/natural-ligands-of-nuclear-receptors/?biosci" />
      <rdf:li resource="https://hstalks.com/t/23653/targeting-the-intestinal-barrier-in-gvhd-and-check/?biosci" />
      <rdf:li resource="https://hstalks.com/t/12730/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci" />
      <rdf:li resource="https://hstalks.com/t/12763/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci" />
      <rdf:li resource="https://hstalks.com/t/24940/unlocking-a-new-class-of-cancer-targets-neoantigen/?biosci" />
      <rdf:li resource="https://hstalks.com/t/23686/blood-cleansing-as-immunotherapy-testing-a-novel-c/?biosci" />
      <rdf:li resource="https://hstalks.com/t/21178/surgical-treatment-of-lymphedema-current-approache/?biosci" />
      
      </rdf:Seq>
    </items>
  </channel>

  <item rdf:about="https://hstalks.com/t/24280/peroxisome-proliferator-activated-receptors-ppar-n/?biosci">
    <title>Peroxisome proliferator-activated receptors: PPARγ (NR1C3) – biological role and drugs [7 mins] </title>
    <link>https://hstalks.com/t/24280/peroxisome-proliferator-activated-receptors-ppar-n/?biosci</link>
    <description>Functions of PPARγ - Role of PPARγ in adipocytes and glucose homeostasis - Role of PPARγ in macrophage functions - PPARγ targeting drugs - PPARγ in MAFLD</description>
    <dc:title>Peroxisome proliferator-activated receptors: PPARγ (NR1C3) – biological role and drugs</dc:title>
    
    <dc:creator>Prof. Dr. Daniel Merk</dc:creator>
    
    <dc:subject>Functions of PPARγ, Role of PPARγ in adipocytes and glucose homeostasis, Role of PPARγ in macrophage functions, PPARγ targeting drugs, PPARγ in MAFLD</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/24313/nuclear-receptor-targeting-drugs/?biosci">
    <title>Nuclear receptor targeting drugs [6 mins] </title>
    <link>https://hstalks.com/t/24313/nuclear-receptor-targeting-drugs/?biosci</link>
    <description>History of NR as drug targets - Distribution of known ligands over the NR families - NR as drug targets - NR ligands in clinical trials - Drug targets among nuclear receptors</description>
    <dc:title>Nuclear receptor targeting drugs</dc:title>
    
    <dc:creator>Prof. Dr. Daniel Merk</dc:creator>
    
    <dc:subject>History of NR as drug targets, Distribution of known ligands over the NR families, NR as drug targets, NR ligands in clinical trials, Drug targets among nuclear receptors</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/26095/immunological-biomarkers-in-cabozantinib-and-nivol/?biosci">
    <title>Immunological biomarkers in cabozantinib and nivolumab treatment for endometrial cancer [19 mins] </title>
    <link>https://hstalks.com/t/26095/immunological-biomarkers-in-cabozantinib-and-nivol/?biosci</link>
    <description>Endometrial cancer immunotherapy - Immune biomarkers - Nivolumab - Cabozantinib - Tumour microenvironment - Macrophages - Personalised cancer treatment - Immunotherapy resistance</description>
    <dc:title>Immunological biomarkers in cabozantinib and nivolumab treatment for endometrial cancer</dc:title>
    
    <dc:creator>Prof. Sacha Gnjatic</dc:creator>
    
    <dc:subject>Endometrial cancer immunotherapy, Immune biomarkers, Nivolumab, Cabozantinib, Tumour microenvironment, Macrophages, Personalised cancer treatment, Immunotherapy resistance</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/24314/natural-ligands-of-nuclear-receptors/?biosci">
    <title>Natural ligands of nuclear receptors [10 mins] </title>
    <link>https://hstalks.com/t/24314/natural-ligands-of-nuclear-receptors/?biosci</link>
    <description>Natural nuclear receptor ligands - Vitamins and steroids as nuclear receptor ligands - Nuclear receptors and nuclear receptors ligands - Negative feedback mechanisms - Lipid and metabolite sensing nuclear receptors - Xenobiotic sensors</description>
    <dc:title>Natural ligands of nuclear receptors</dc:title>
    
    <dc:creator>Prof. Dr. Daniel Merk</dc:creator>
    
    <dc:subject>Natural nuclear receptor ligands, Vitamins and steroids as nuclear receptor ligands, Nuclear receptors and nuclear receptors ligands, Negative feedback mechanisms, Lipid and metabolite sensing nuclear receptors, Xenobiotic sensors</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/23653/targeting-the-intestinal-barrier-in-gvhd-and-check/?biosci">
    <title>Targeting the intestinal barrier in GVHD and checkpoint colitis [20 mins] </title>
    <link>https://hstalks.com/t/23653/targeting-the-intestinal-barrier-in-gvhd-and-check/?biosci</link>
    <description>Acute graft-versus-host disease (aGVHD): Clinical presentation - Intestinal inflammation during aGVHD - Treatment of aGVHD - Kinase targets in GVHD - REACH2 trial - Colitis and other irAEs after immune checkpoint blockade - ECP is an effective therapy for inflammatory diseases - Arginase-1 is central in ECP-induced immunomodulation</description>
    <dc:title>Targeting the intestinal barrier in GVHD and checkpoint colitis</dc:title>
    
    <dc:creator>Prof. Robert Zeiser</dc:creator>
    
    <dc:subject>Acute graft-versus-host disease (aGVHD): Clinical presentation, Intestinal inflammation during aGVHD, Treatment of aGVHD, Kinase targets in GVHD, REACH2 trial, Colitis and other irAEs after immune checkpoint blockade, ECP is an effective therapy for inflammatory diseases, Arginase-1 is central in ECP-induced immunomodulation</dc:subject>
    <dc:date>2026-10-29</dc:date>
    <prism:publicationDate>2026-10-29</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/12730/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci">
    <title>Bladder cancer: types, risk factors, diagnosis, treatment and prevention: introduction to bladder cancer [36 mins] </title>
    <link>https://hstalks.com/t/12730/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci</link>
    <description>Bladder cancer: incidence and epidemiology - Bladder cancer risk factors - Lynch syndrome - Bladder cancer: pathology, staging and diagnosis - Initial therapy for NMIBC (non-muscle-invasive bladder cancer)</description>
    <dc:title>Bladder cancer: types, risk factors, diagnosis, treatment and prevention: introduction to bladder cancer</dc:title>
    
    <dc:creator>Prof. Guru P. Sonpavde</dc:creator>
    
    <dc:subject>Bladder cancer: incidence and epidemiology, Bladder cancer risk factors, Lynch syndrome, Bladder cancer: pathology, staging and diagnosis, Initial therapy for NMIBC (non-muscle-invasive bladder cancer)</dc:subject>
    <dc:date>2026-09-30</dc:date>
    <prism:publicationDate>2026-09-30</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/12763/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci">
    <title>Bladder cancer: types, risk factors, diagnosis, treatment and prevention: further clinical trials [37 mins] </title>
    <link>https://hstalks.com/t/12763/bladder-cancer-types-risk-factors-diagnosis-treatm/?biosci</link>
    <description>Ongoing clinical trials for bladder cancer - Enfortumab-vedotin &amp; pembrolizumab as first-line therapy - Disitamab vedotin &amp; toripalimab (PD1 inhibitor) for the treatment of metastatic UC - Erdafitinib for the treatment of metastatic UC with FGFR2/3 mutations/fusions - Remission with cisplatin-based NAC - mRNA-4157 (V940): customizable individualized mRNA immunotherapy - Adjuvant chemotherapy - Neoadjuvant Chemo-IO combination therapy</description>
    <dc:title>Bladder cancer: types, risk factors, diagnosis, treatment and prevention: further clinical trials</dc:title>
    
    <dc:creator>Prof. Guru P. Sonpavde</dc:creator>
    
    <dc:subject>Ongoing clinical trials for bladder cancer, Enfortumab-vedotin &amp; pembrolizumab as first-line therapy, Disitamab vedotin &amp; toripalimab (PD1 inhibitor) for the treatment of metastatic UC, Erdafitinib for the treatment of metastatic UC with FGFR2/3 mutations/fusions, Remission with cisplatin-based NAC, mRNA-4157 (V940): customizable individualized mRNA immunotherapy, Adjuvant chemotherapy, Neoadjuvant Chemo-IO combination therapy</dc:subject>
    <dc:date>2026-09-30</dc:date>
    <prism:publicationDate>2026-09-30</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/24940/unlocking-a-new-class-of-cancer-targets-neoantigen/?biosci">
    <title>Unlocking a new class of cancer targets: neoantigens from RNA splicing [8 mins] </title>
    <link>https://hstalks.com/t/24940/unlocking-a-new-class-of-cancer-targets-neoantigen/?biosci</link>
    <description>Public neoantigens - Alternative splicing-derived neojunctions - Cancer immunotherapy - Brain tumours (gliomas) - T-cell receptor (TCR)-based therapy - Cancer vaccines - Intratumour heterogeneity - Tumour-specific antigens - Human leukocyte antigen (HLA) presentation - Off-the-shelf immunotherapies</description>
    <dc:title>Unlocking a new class of cancer targets: neoantigens from RNA splicing</dc:title>
    
    <dc:creator>Dr. Hideho Okada</dc:creator>
    
    <dc:subject>Public neoantigens, Alternative splicing-derived neojunctions, Cancer immunotherapy, Brain tumours (gliomas), T-cell receptor (TCR)-based therapy, Cancer vaccines, Intratumour heterogeneity, Tumour-specific antigens, Human leukocyte antigen (HLA) presentation, Off-the-shelf immunotherapies</dc:subject>
    <dc:date>2026-08-31</dc:date>
    <prism:publicationDate>2026-08-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/23686/blood-cleansing-as-immunotherapy-testing-a-novel-c/?biosci">
    <title>Blood cleansing as immunotherapy: testing a novel cancer vaccine strategy [18 mins] </title>
    <link>https://hstalks.com/t/23686/blood-cleansing-as-immunotherapy-testing-a-novel-c/?biosci</link>
    <description>Cancer vaccines - Cancer immunotherapy - Ovarian cancer - Tumour antigens - Whole-cell vaccines - T-cell activation - Tumour microenvironment - Clinical development of immunotherapies</description>
    <dc:title>Blood cleansing as immunotherapy: testing a novel cancer vaccine strategy</dc:title>
    
    <dc:creator>Prof. Raymond Goodrich</dc:creator>
    
    <dc:subject>Cancer vaccines, Cancer immunotherapy, Ovarian cancer, Tumour antigens, Whole-cell vaccines, T-cell activation, Tumour microenvironment, Clinical development of immunotherapies</dc:subject>
    <dc:date>2026-08-31</dc:date>
    <prism:publicationDate>2026-08-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

  <item rdf:about="https://hstalks.com/t/21178/surgical-treatment-of-lymphedema-current-approache/?biosci">
    <title>Surgical treatment of lymphedema: current approaches &amp; future directions [41 mins] </title>
    <link>https://hstalks.com/t/21178/surgical-treatment-of-lymphedema-current-approache/?biosci</link>
    <description>The train station analogy - Lymph node transplant - Lymphovenous bypass - Excisional procedure - Axillary reverse mapping (ARM) - Lymphatic microsurgical preventive healing approach (LYMPHA) - Immediate lymphatic reconstruction - Predisposition to lymphedema - Mascagni Sappey pathway - Axillary and cephalic pathways - Long vs. short bundle - Mapping the lymphatic system</description>
    <dc:title>Surgical treatment of lymphedema: current approaches &amp; future directions</dc:title>
    
    <dc:creator>Dr. Dhruv Singhal</dc:creator>
    
    <dc:subject>The train station analogy, Lymph node transplant, Lymphovenous bypass, Excisional procedure, Axillary reverse mapping (ARM), Lymphatic microsurgical preventive healing approach (LYMPHA), Immediate lymphatic reconstruction, Predisposition to lymphedema, Mascagni Sappey pathway, Axillary and cephalic pathways, Long vs. short bundle, Mapping the lymphatic system</dc:subject>
    <dc:date>2026-08-31</dc:date>
    <prism:publicationDate>2026-08-31</prism:publicationDate>
    <prism:publicationName>The Biomedical &amp; Life Sciences Collection</prism:publicationName>
  </item>

</rdf:RDF>
